



Referenzliste | Liste des Références

1. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J*. 2016;37(1):67–119. doi:10.1093/eurheartj/ehv31726320113
2. Maeder MT, Kleiner R, Weilenmann D, Schoch OD. Pulmonary hypertension associated with left heart and lung diseases. *Cardiovasc Med*. 2014;17:320–7.
3. Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiéry JL. Left ventricular heart failure and pulmonary hypertension. *Eur Heart J*. 2016;37(12):942–54. doi:10.1093/eurheartj/ehv51226508169
4. Vachiéry JL, Adir Y, Barberà JA, Champion H, Coghlan G, Cottin V, et al. Pulmonary hypertension due to left heart diseases. *J Am Coll Cardiol*. 2013;62(25, Suppl):D100–8. doi:10.1016/j.jacc.2013.10.03324355634
5. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. *J Am Coll Cardiol*. 2001;37(1):183–8. doi:10.1016/S0735-1097(00)01102-511153735
6. Melenovsky V, Hwang SJ, Lin G, Redfield MM, Borlaug BA. Right heart dysfunction in heart failure with preserved ejection fraction. *Eur Heart J*. 2014;35(48):3452–62. doi:10.1093/eurheartj/ehu19324875795
7. Kammerlander AA, Marzluf BA, Graf A, Bachmann A, Kocher A, Bonderman D, et al. Right ventricular dysfunction, but not tricuspid regurgitation, is associated with outcome late after left heart valve procedure. *J Am Coll Cardiol*. 2014;64(24):2633–42. doi:10.1016/j.jacc.2014.09.06225524343
8. Maeder MT, Kleiner R, Weilenmann D. Severely worsening dyspnea after initiation of macitentan therapy for pulmonary arterial hypertension. *Int J Cardiol*. 2016;202:244–5. doi:10.1016/j.ijcard.2015.08.13226402452
9. Boilson BA, Schirger JA, Borlaug BA. Caveat medicus! Pulmonary hypertension in the elderly: a word of caution. *Eur J Heart Fail*. 2010;12(1):89–93. doi:10.1093/eurjhf/hfp17120023048
10. Thenappan T, Shah SJ, Gomberg-Maitland M, Collander B, Vallakati A, Shroff P, et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. *Circ Heart Fail*. 2011;4(3):257–65. doi:10.1161/CIRCHEARTFAILURE.110.95880121411741
11. Opatowsky AR, Ojeda J, Rogers F, Prasanna V, Clair M, Moko L, et al. A simple echocardiographic prediction rule for hemodynamics in pulmonary hypertension. *Circ Cardiovasc Imaging*. 2012;5(6):765–75. doi:10.1161/CIRCIMAGING.112.97665422914595



12. D'Alto M, Romeo E, Argiento P, Pavelescu A, Mélot C, D'Andrea A, et al. Echocardiographic prediction of pre- versus postcapillary pulmonary hypertension. *J Am Soc Echocardiogr.* 2015;28(1):108–15. doi:10.1016/j.echo.2014.09.00425441329
13. Bonderman D, Wexberg P, Heinzl H, Lang IM. Non-invasive algorithms for the diagnosis of pulmonary hypertension. *Thromb Haemost.* 2012;108(6):1037–41. doi:10.1160/TH12-04-023923052634
14. Abbas AE, Fortuin FD, Schiller NB, Appleton CP, Moreno CA, Lester SJ. A simple method for noninvasive estimation of pulmonary vascular resistance. *J Am Coll Cardiol.* 2003;41(6):1021–7. doi:10.1016/S0735-1097(02)02973X12651052
15. Maeder MT, Karapanagiotidis S, Dewar EM, Gamboni SE, Htun N, Kaye DM. Accuracy of Doppler echocardiography to estimate key hemodynamic variables in subjects with normal left ventricular ejection fraction. *J Card Fail.* 2011;17(5):405–12. doi:10.1016/j.cardfail.2010.12.00321549298
16. Maeder MT, Kaye DM. Heart failure with normal left ventricular ejection fraction. *J Am Coll Cardiol.* 2009;53(11):905–18. doi:10.1016/j.jacc.2008.12.00719281919
17. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. *Eur Heart J.* 2007;28(20):2539–50. doi:10.1093/eurheartj/ehm03717428822
18. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al.; Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J.* 2016;37(27):2129–200. doi:10.1093/eurheartj/ehw12827206819
19. Lüscher TF, Enseleit F, Pacher R, Mitrovic V, Schulze MR, Willenbrock R, et al.; Heart Failure ET(A) Receptor Blockade Trial. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). *Circulation.* 2002;106(21):2666–72. doi:10.1161/01.CIR.0000038497.80095.E112438291
20. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, et al.; EARTH investigators. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. *Lancet.* 2004;364(9431):347–54. doi:10.1016/S0140-6736(04)16723-815276394
21. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. *J Am Coll Cardiol.* 2004;44(12):2339–48. doi:10.1016/j.jacc.2004.09.04115607396
22. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure



and secondary pulmonary hypertension. *Circulation*. 2007;116(14):1555–62.
doi:10.1161/CIRCULATIONAHA.107.71637317785618

23. Bonderman D, Ghio S, Felix SB, Ghofrani HA, Michelakis E, Mitrovic V, et al.; Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial (LEPHT) Study Group. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. *Circulation*. 2013;128(5):502–11.
doi:10.1161/CIRCULATIONAHA.113.00145823775260

24. Cooper TJ, Guazzi M, Al-Mohammad A, Amir O, Bengal T, Cleland JG, et al. Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design. *Eur J Heart Fail*. 2013;15(1):119–22.
doi:10.1093/eurjhf/hfs15223097067

25. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. *Circulation*. 2011;124(2):164–74. doi:10.1161/CIRCULATIONAHA.110.98386621709061

26. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, et al.; RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. *JAMA*. 2013;309(12):1268–77. doi:10.1001/jama.2013.202423478662

27. Hoendermis ES, Liu LC, Hummel YM, van der Meer P, de Boer RA, Berger RM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. *Eur Heart J*. 2015;36(38):2565–73. doi: 10.1093/eurheartj/ehv336.

28. Tufaro C, et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. *Chest*. 2014;146(5):1274–85. doi:10.1378/chest.14-010624991733